• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Tricida Inc. (Amendment)

    10/19/22 5:07:27 PM ET
    $TCDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TCDA alert in real time by email
    SC 13D/A 1 tm2228500d1_sc13da.htm SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 5)

     

     

     

    Tricida, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    89610F101

    (CUSIP Number)

     

    Sibling Capital Ventures LLC

    c/o Brian Isern

    2033 6th Ave, Suite 330

    Seattle, WA 98121

    Tel: (504) 715-8335 

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    October 12, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ¨

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 89610F101

     

    1

    NAME OF REPORTING PERSONS

     

    SIBLING CAPITAL VENTURES LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    AF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

    NUMBER OF

    UNITS

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    -0-

    8

    SHARED VOTING POWER

     

    702,411 (1)

    9

    SOLE DISPOSITIVE POWER

     

    -0-

    10

    SHARED DISPOSITIVE POWER

     

    702,411 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    702,411 (1)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.3% (2)

    14

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) Sibling Capital Fund II-A L.P. is a direct beneficial owner of 702,411 shares of Common Stock. As the sole general partner of Sibling Capital Fund II-A L.P., Sibling Capital Ventures LLC may be deemed to have shared voting and/or dispositive power with respect to such shares.
    (2) Based on 55,668,880 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

      

     

     

     

    CUSIP No. 89610F101

     

    1

    NAME OF REPORTING PERSONS

     

    SIBLING CAPITAL VENTURES II LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    AF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

    NUMBER OF

    UNITS

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    -0-

    8

    SHARED VOTING POWER

     

    2,223,350 (1)

    9

    SOLE DISPOSITIVE POWER

     

    -0-

    10

    SHARED DISPOSITIVE POWER

     

    2,223,350 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,223,350 (1)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    4.0% (2)

    14

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) Sibling Capital Fund II-B L.P. is a direct beneficial owner of 2,223,350 shares of Common Stock. As the sole general partner of Sibling Capital Fund II-B L.P., Sibling Capital Ventures II LLC may be deemed to have shared voting and/or dispositive power with respect to such shares.
    (2) Based on 55,668,880 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101

     

    1

    NAME OF REPORTING PERSONS

     

    SIBLING CAPITAL VENTURES III LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    AF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

    NUMBER OF

    UNITS

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    -0-

    8

    SHARED VOTING POWER

     

    1,575,195 (1)

    9

    SOLE DISPOSITIVE POWER

     

    -0-

    10

    SHARED DISPOSITIVE POWER

     

    1,575,195 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,575,195 (1)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    2.8% (2)

    14

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) Sibling Capital Fund II-C L.P. is a direct beneficial owner of 1,575,195 shares of Common Stock. As the sole general partner of Sibling Capital Fund II-C L.P., Sibling Capital Ventures III LLC may be deemed to have shared voting and/or dispositive power with respect to such shares.
    (2) Based on 55,668,880 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101

     

    1

    NAME OF REPORTING PERSONS

     

    SIBLING CAPITAL VENTURES IV LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    AF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

    NUMBER OF

    UNITS

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    -0-

    8

    SHARED VOTING POWER

     

    599,379 (1)

    9

    SOLE DISPOSITIVE POWER

     

    -0-

    10

    SHARED DISPOSITIVE POWER

     

    599,379 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    599,379 (1)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.1% (2)

    14

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) Sibling Capital Fund II-D L.P. is a direct beneficial owner of 599,379 shares of Common Stock. As the sole general partner of Sibling Capital Fund II-D L.P., Sibling Capital Ventures IV LLC may be deemed to have shared voting and/or dispositive power with respect to such shares.
    (2) Based on 55,668,880 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101

     

    1

    NAME OF REPORTING PERSONS

     

    SIBLING CAPITAL FUND II-A L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

    NUMBER OF

    UNITS

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    702,411

    8

    SHARED VOTING POWER

     

    -0-

    9

    SOLE DISPOSITIVE POWER

     

    702,411

    10

    SHARED DISPOSITIVE POWER

     

    -0-

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    702,411

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.3% (1)

    14

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Based on 55,668,880 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101

     

    1

    NAME OF REPORTING PERSONS

     

    SIBLING CAPITAL FUND II-B L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

    NUMBER OF

    UNITS

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    2,223,350

    8

    SHARED VOTING POWER

     

    -0-

    9

    SOLE DISPOSITIVE POWER

     

    2,223,350

    10

    SHARED DISPOSITIVE POWER

     

    -0-

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,223,350

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    4.0% (1)

    14

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Based on 55,668,880 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101

     

    1

    NAME OF REPORTING PERSONS

     

    SIBLING CAPITAL FUND II-C L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

    NUMBER OF

    UNITS

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    1,575,195

    8

    SHARED VOTING POWER

     

    -0-

    9

    SOLE DISPOSITIVE POWER

     

    1,575,195

    10

    SHARED DISPOSITIVE POWER

     

    -0-

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,575,195

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    2.8% (1)

    14

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Based on 55,668,880 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101

     

    1

    NAME OF REPORTING PERSONS

     

    SIBLING CAPITAL FUND II-D L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

    NUMBER OF

    UNITS

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    599,379

    8

    SHARED VOTING POWER

     

    -0-

    9

    SOLE DISPOSITIVE POWER

     

    599,379

    10

    SHARED DISPOSITIVE POWER

     

    -0-

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    599,379

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    1.1% (1)

    14

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Based on 55,668,880 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101

     

    1

    NAME OF REPORTING PERSONS

     

    SIBLING INSIDERS II LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    AF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

    NUMBER OF

    UNITS

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    -0-

    8

    SHARED VOTING POWER

     

    463,158 (1)

    9

    SOLE DISPOSITIVE POWER

     

    -0-

    10

    SHARED DISPOSITIVE POWER

     

    463,158 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    463,158 (1)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.8% (2)

    14

    TYPE OF REPORTING PERSON

     

    OO

     

    (1) Sibling Insiders Fund II L.P. is a direct beneficial owner of 463,158 shares of Common Stock. As the sole general partner of Sibling Insiders Fund II L.P., Sibling Insiders II LLC may be deemed to have shared voting and/or dispositive power with respect to such shares.
    (2) Based on 55,668,880 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101

     

    1

    NAME OF REPORTING PERSONS

     

    SIBLING INSIDERS FUND II L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    WC

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    DELAWARE, UNITED STATES

    NUMBER OF

    UNITS

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    463,158

    8

    SHARED VOTING POWER

     

    -0-

    9

    SOLE DISPOSITIVE POWER

     

    463,158

    10

    SHARED DISPOSITIVE POWER

     

    -0-

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    463,158

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    0.8% (1)

    14

    TYPE OF REPORTING PERSON

     

    PN

     

    (1) Based on 55,668,880 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101

     

    1

    NAME OF REPORTING PERSONS

     

    BRIAN M. ISERN

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) x

     

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    AF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    UNITED STATES

    NUMBER OF

    UNITS

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

     

    -0-

    8

    SHARED VOTING POWER

     

    5,563,493 (1)

    9

    SOLE DISPOSITIVE POWER

     

    -0-

    10

    SHARED DISPOSITIVE POWER

     

    5,563,493 (1)

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,563,493 (1)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    10.0% (2)

    14

    TYPE OF REPORTING PERSON

     

    IN

     

    (1) As sole manager of Sibling Capital Ventures LLC, Sibling Capital Ventures II LLC, Sibling Capital Ventures III LLC, Sibling Capital Ventures IV LLC and Sibling Insiders II LLC, Brian M. Isern may be deemed to have shared voting and/or dispositive power with respect to shares held by Sibling Capital Fund II-A L.P., Sibling Capital Fund II-B L.P., Sibling Capital Fund II-C L.P., Sibling Capital Fund II-D L.P. and Sibling Insiders Fund II L.P.
    (2) Based on 55,668,880 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    Explanatory Note

     

    This Amendment No. 5 hereby amends the Schedule 13D first filed by the Reporting Persons (as defined below) on July 12, 2018, as amended by Amendment No. 1 to the Schedule 13D filed on April 11, 2019, Amendment No. 2 to the Schedule 13D filed on November 27, 2019, Amendment No. 3 to the Schedule 13D filed on November 23, 2021, and Amendment No. 4 to the Schedule 13D filed on March 24, 2022 (as amended, the “Statement”).  The securities to which the Statement relates are the shares of common stock, par value $0.001 per share (the “Common Stock”), of Tricida, Inc., a Delaware corporation (the “Issuer”). Except as otherwise provided herein, each Item of the Schedule 13D remains unchanged. Capitalized terms used herein but not defined in this Amendment No. 5 shall have the meaning ascribed to such term in the Schedule 13D.

     

    Item 2. IDENTITY AND BACKGROUND

     

    (a)

     

    This Amendment No. 5 is being filed jointly by:

     

      (i) Sibling Capital Ventures LLC, a Delaware limited liability company (“SCV”)
      (ii) Sibling Capital Ventures II LLC, a Delaware limited liability company (“SCV II”)
      (iii) Sibling Capital Ventures III LLC, a Delaware limited liability company (“SCV III”)
      (iv) Sibling Capital Ventures IV LLC, a Delaware limited liability company (“SCV IV”)
      (v) Sibling Capital Fund II-A L.P., a Delaware limited partnership (“Sibling A”)
      (vi) Sibling Capital Fund II-B L.P., a Delaware limited partnership (“Sibling B”)
      (vii) Sibling Capital Fund II-C L.P., a Delaware limited partnership (“Sibling C”)
      (viii) Sibling Capital Fund II-D L.P., a Delaware limited partnership (“Sibling D”)
      (ix) Sibling Insiders II LLC, a Delaware limited liability company (“Sibling Insiders LLC”)
      (x) Sibling Insiders Fund II L.P., a Delaware limited partnership (“Sibling Insiders Fund”)
      (xi) Brian M. Isern, a United States citizen (“Mr. Isern”)

     

    The General Partners, the Funds and Mr. Isern are collectively referred to herein as the “Reporting Persons” and individually as a “Reporting Person.”

     

    The Reporting Persons, may be deemed part of a group within the meaning of Section 13(d) of the Act. Accordingly, such group may be deemed to collectively beneficially own 5,563,493 shares of Common Stock, representing approximately 9.99% of the Common Stock outstanding as of August 4, 2022. The filing of this Amendment No. 5 shall not be construed as an admission that the Reporting Persons are part of a group within the meaning of Section 13(d) of the Act.

     

    (b)

     

    The principal business address of each Reporting Person is 2033 6th Ave, Suite 330, Seattle, WA 98121.

     

     

     

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER

     

    (a) - (b)

     

    The aggregate number and percentage of Common Stock beneficially owned by the Reporting Persons are as follows:

     

    Sibling Capital Ventures LLC       
            
    Amount beneficially owned:   702,411  (1)
    Percent of class:   1.3% (7)
    Number of shares as to which the person has:       
    Sole power to vote or direct the vote:   0   
    Shared power to vote or direct the vote:   702,411  (1)
    Sole power to dispose or direct the disposition of:   0   
    Shared power to dispose or direct the disposition of:   702,411  (1)
            
    Sibling Capital Ventures II LLC       
            
    Amount beneficially owned:   2,223,350  (2)
    Percent of class:   4.0% (7)
    Number of shares as to which the person has:       
    Sole power to vote or direct the vote:   0   
    Shared power to vote or direct the vote:   2,223,350  (2)
    Sole power to dispose or direct the disposition of:   0   
    Shared power to dispose or direct the disposition of:   2,223,350  (2)
            
    Sibling Capital Ventures III LLC       
            
    Amount beneficially owned:   1,575,195  (3)
    Percent of class:   2.8% (7)
    Number of shares as to which the person has:       
    Sole power to vote or direct the vote:   0   
    Shared power to vote or direct the vote:   1,575,195  (3)
    Sole power to dispose or direct the disposition of:   0   
    Shared power to dispose or direct the disposition of:   1,575,195  (3)
            
    Sibling Capital Ventures IV LLC       
            
    Amount beneficially owned:   599,379  (4)
    Percent of class:   1.1% (7)
    Number of shares as to which the person has:       
    Sole power to vote or direct the vote:   0   
    Shared power to vote or direct the vote:   599,379  (4)
    Sole power to dispose or direct the disposition of:   0   
    Shared power to dispose or direct the disposition of:   599,379  (4)
            
    Sibling Capital Fund II-A L.P.       
            
    Amount beneficially owned:   702,411   
    Percent of class:   1.3% (7)
    Number of shares as to which the person has:       
    Sole power to vote or direct the vote:   702,411   
    Shared power to vote or direct the vote:   0   
    Sole power to dispose or direct the disposition of:   702,411   
    Shared power to dispose or direct the disposition of:   0   
            
    Sibling Capital Fund II-B L.P.       
            
    Amount beneficially owned:   2,223,350   
    Percent of class:   4.0% (7)
    Number of shares as to which the person has:       
    Sole power to vote or direct the vote:   2,223,350   
    Shared power to vote or direct the vote:   0   
    Sole power to dispose or direct the disposition of:   2,223,350   
    Shared power to dispose or direct the disposition of:   0   

     

     

     

     

    Sibling Capital Fund II-C L.P.       
            
    Amount beneficially owned:   1,575,195   
    Percent of class:   2.8% (7)
    Number of shares as to which the person has:       
    Sole power to vote or direct the vote:   1,575,195   
    Shared power to vote or direct the vote:   0   
    Sole power to dispose or direct the disposition of:   1,575,195   
    Shared power to dispose or direct the disposition of:   0   
            
    Sibling Capital Fund II-D L.P.       
            
    Amount beneficially owned:   599,379   
    Percent of class:   1.1% (7)
    Number of shares as to which the person has:       
    Sole power to vote or direct the vote:   599,379   
    Shared power to vote or direct the vote:   0   
    Sole power to dispose or direct the disposition of:   599,379   
    Shared power to dispose or direct the disposition of:   0   
            
    Sibling Insiders II LLC       
            
    Amount beneficially owned:   463,158  (5)
    Percent of class:   0.8% (7)
    Number of shares as to which the person has:       
    Sole power to vote or direct the vote:   0   
    Shared power to vote or direct the vote:   463,158  (5)
    Sole power to dispose or direct the disposition of:   0   
    Shared power to dispose or direct the disposition of:   463,158  (5)
            
    Sibling Insiders Fund II L.P.       
            
    Amount beneficially owned:   463,158   
    Percent of class:   0.8% (7)
    Number of shares as to which the person has:       
    Sole power to vote or direct the vote:   463,158   
    Shared power to vote or direct the vote:   0   
    Sole power to dispose or direct the disposition of:   463,158   
    Shared power to dispose or direct the disposition of:   0   
            
    Brian M. Isern       
            
    Amount beneficially owned:   5,563,493  (6)
    Percent of class:   10.0% (7)
    Number of shares as to which the person has:       
    Sole power to vote or direct the vote:   0   
    Shared power to vote or direct the vote:   5,563,493  (6)
    Sole power to dispose or direct the disposition of:   0   
    Shared power to dispose or direct the disposition of:   5,563,493  (6)

     

      (1) Sibling A is a direct beneficial owner of 702,411 shares of Common Stock. As the sole general partner of Sibling A, SCV may be deemed to have shared voting and/or dispositive power with respect to such shares.
      (2) Sibling B is a direct beneficial owner of 2,223,350 shares of Common Stock. As the sole general partner of Sibling B, SCV II may be deemed to have shared voting and/or dispositive power with respect to such shares.
      (3) Sibling C is a direct beneficial owner of 1,575,195 shares of Common Stock. As the sole general partner of Sibling C, SCV III may be deemed to have shared voting and/or dispositive power with respect to such shares.
      (4) Sibling D is a direct beneficial owner of 599,379 shares of Common Stock. As the sole general partner of Sibling D, SCV IV may be deemed to have shared voting and/or dispositive power with respect to such shares.

     

     

     

     

      (5) Sibling Insiders Fund is a direct beneficial owner of 463,158 shares of Common Stock. As the sole general partner of Sibling Insiders Fund, Sibling Insiders LLC may be deemed to have shared voting and/or dispositive power with respect to such shares.
      (6) As sole manager of SCV, SCV II, SCV III, SCV IV and Sibling Insiders LLC, Mr. Isern may be deemed to have shared voting and/or dispositive power with respect to shares held by Sibling A, Sibling B, Sibling C, Sibling D and Sibling Insiders Fund.
      (7) Based on 55,668,880 shares of Common Stock outstanding as of August 4, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

    (c)

     

    Annex A hereof sets forth the transactions by the Reporting Persons in the securities of the Issuer from the 60 days prior to the date of the event which requires the filing of this Amendment No. 5 and through and including the date hereof. Except as otherwise disclosed on Annex A, none of the Reporting Persons, nor, to the best of the Reporting Persons’ knowledge, any of their respective executive officers or directors, as applicable, has acquired or disposed of, any securities of the Issuer from the 60 days prior to the date of the event which requires the filing of this Amendment No. 5 and through and including the date hereof.

     

    Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

     

    Exhibit A of the Statement is replaced with the Amended and Restated Joint Filing Agreement, dated October 19, 2022, by and among the Reporting Persons, filed with this Amendment No. 5.

     

    Item 7. MATERIAL TO BE FILED AS EXHIBITS

     

    Exhibit A:   Amended and Restated Joint Filing Agreement

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: October 19, 2022

     

      SIBLING CAPITAL VENTURES LLC
         
      By:

    /s/ Brian M. Isern

        Brian M. Isern
        President
       
      SIBLING CAPITAL VENTURES II LLC
         
      By:

    /s/ Brian M. Isern 

        Brian M. Isern
        President
       
      SIBLING CAPITAL VENTURES III LLC
         
      By:

    /s/ Brian M. Isern 

        Brian M. Isern
        President
       
      SIBLING CAPITAL VENTURES IV LLC
         
      By:

    /s/ Brian M. Isern 

        Brian M. Isern
        President
       
     

    /s/ Brian M. Isern 

      Brian M. Isern, in his individual capacity
         
      SIBLING CAPITAL FUND II-A L.P.
         
      By: Sibling Capital Ventures LLC, its general partner
         
      By:

    /s/ Brian M. Isern 

        Brian M. Isern
        President
         
      SIBLING CAPITAL FUND II-B L.P.
       
      By: Sibling Capital Ventures II LLC, its general partner
         
      By:

    /s/ Brian M. Isern 

        Brian M. Isern
        President

     

     

     

     

      SIBLING CAPITAL FUND II-C L.P.
       
      By: Sibling Capital Ventures III LLC, its general partner
         
      By:

    /s/ Brian M. Isern 

        Brian M. Isern
        President
       
      SIBLING CAPITAL FUND II-D L.P.
       
      By: Sibling Capital Ventures IV LLC, its general partner
         
      By:

    /s/ Brian M. Isern 

        Brian M. Isern
        President
       
      SIBLING INSIDERS II LLC
         
      By:

    /s/ Brian M. Isern 

        Brian M. Isern
        President
       
      SIBLING INSIDERS FUND II L.P.
       
      By: Sibling Insiders II LLC, its general partner
         
      By:

    /s/ Brian M. Isern 

        Brian M. Isern
        President

     

     

     

     

    Annex A

     

    Schedule of Transactions

     

    Reporting Person

      Transaction
    Date
      Title of
    Security
      Amount
    Sold
       Price  Transaction
    Type
    Sibling Capital Fund II-A L.P. (1)  8/15/2022  Common Stock   5,601   (4)  Open Market Sale
    Sibling Capital Fund II-B L.P. (2)  8/15/2022  Common Stock   19,416   (4)  Open Market Sale
    Sibling Capital Fund II-C L.P. (3)  8/15/2022  Common Stock   12,322   (4)  Open Market Sale
    Sibling Capital Fund II-A L.P. (1)  8/16/2022  Common Stock   4,920   (5)  Open Market Sale
    Sibling Capital Fund II-B L.P. (2)  8/16/2022  Common Stock   17,056   (5)  Open Market Sale
    Sibling Capital Fund II-C L.P. (3)  8/16/2022  Common Stock   10,824   (5)  Open Market Sale
    Sibling Capital Fund II-A L.P. (1)  9/30/2022  Common Stock   14,995   (6)  Open Market Sale
    Sibling Capital Fund II-B L.P. (2)  9/30/2022  Common Stock   51,984   (6)  Open Market Sale
    Sibling Capital Fund II-C L.P. (3)  9/30/2022  Common Stock   32,989   (6)  Open Market Sale
    Sibling Capital Fund II-A L.P. (1)  10/3/2022  Common Stock   10,349   (7)  Open Market Sale
    Sibling Capital Fund II-B L.P. (2)  10/3/2022  Common Stock   35,877   (7)  Open Market Sale
    Sibling Capital Fund II-C L.P. (3)  10/3/2022  Common Stock   22,768   (7)  Open Market Sale
    Sibling Capital Fund II-B L.P. (2)  10/11/2022  Common Stock   95,366   (8)  Open Market Sale
    Sibling Capital Fund II-C L.P. (3)  10/11/2022  Common Stock   23,019   (8)  Open Market Sale
    Sibling Capital Fund II-B L.P. (2)  10/12/2022  Common Stock   171,006   (9)  Open Market Sale
    Sibling Capital Fund II-C L.P. (3)  10/12/2022  Common Stock   41,277   (9)  Open Market Sale
    Sibling Capital Fund II-B L.P. (2)  10/13/2022  Common Stock   23,628   (10)  Open Market Sale
    Sibling Capital Fund II-C L.P. (3)  10/13/2022  Common Stock   5,704   (10)  Open Market Sale

     

    (1) The shares were sold by Sibling Capital Fund II-A L.P. (“Sibling A”). Sibling Capital Ventures LLC (“SCV”) is the sole general partner of Sibling A. As sole manager of SCV, Brian M. Isern may be deemed to be an indirect beneficial owner of such shares.

    (2) The shares were sold by Sibling Capital Fund II-B L.P. (“Sibling B”). Sibling Capital Ventures II LLC (“SCV II”) is the sole general partner of Sibling B. As sole manager of SCV II, Brian M. Isern may be deemed to be an indirect beneficial owner of such shares.

    (3) The shares were sold by Sibling Capital Fund II-C L.P. (“Sibling C”). Sibling Capital Ventures III LLC (“SCV III”) is the sole general partner of Sibling C. As sole manager of SCV III, Brian M. Isern may be deemed to be an indirect beneficial owner of such shares.

    (4) These shares were sold in multiple transactions at prices ranging from $13.15 to $13.75, inclusive.

    (5) These shares were sold in multiple transactions at prices ranging from $13.44 to $13.74, inclusive.

    (6) These shares were sold in multiple transactions at prices ranging from $10.40 to $11.01, inclusive.

    (7) These shares were sold in multiple transactions at prices ranging from $10.61 to $11.52, inclusive.

    (8) These shares were sold in multiple transactions at prices ranging from $11.65 to $12.38, inclusive.

    (9) These shares were sold in multiple transactions at prices ranging from $12.18 to $13.06, inclusive.

    (10) These shares were sold in multiple transactions at prices ranging from $11.55 to $12.20, inclusive.

     

     

     

     

    Exhibit A

     

    AMENDED AND RESTATED JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

     

    In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below (the “Parties”) agree to the joint filing on behalf of each of them of a Statement on Schedule 13D, Amendment No. 5, dated October 19, 2022 (and including any further amendments thereto, the “Statement”), with respect to the common stock, par value $0.001 per share, of Tricida, Inc., a Delaware corporation. This Amended and Restated Joint Filing Agreement shall be filed as an Exhibit to the Statement filed by the Parties.

     

      SIBLING CAPITAL VENTURES LLC
         
      By:

    /s/ Brian M. Isern

        Brian M. Isern
        President
       
      SIBLING CAPITAL VENTURES II LLC
         
      By:

    /s/ Brian M. Isern

        Brian M. Isern
        President
       
      SIBLING CAPITAL VENTURES III LLC
         
      By:

    /s/ Brian M. Isern

        Brian M. Isern
        President
       
      SIBLING CAPITAL VENTURES IV LLC
         
      By:

    /s/ Brian M. Isern

        Brian M. Isern
        President
       
     

    /s/ Brian M. Isern

      Brian M. Isern, in his individual capacity
         
      SIBLING CAPITAL FUND II-A L.P.
         
      By: Sibling Capital Ventures LLC, its general partner
         
      By:

    /s/ Brian M. Isern

        Brian M. Isern
        President
       
      SIBLING CAPITAL FUND II-B L.P.
       
      By: Sibling Capital Ventures II LLC, its general partner
         
      By:

    /s/ Brian M. Isern

        Brian M. Isern
        President

     

     

     

     

      SIBLING CAPITAL FUND II-C L.P.
       
      By: Sibling Capital Ventures III LLC, its general partner
         
      By:

    /s/ Brian M. Isern

        Brian M. Isern
        President
       
      SIBLING CAPITAL FUND II-D L.P.
       
      By: Sibling Capital Ventures IV LLC, its general partner
         
      By:

    /s/ Brian M. Isern

        Brian M. Isern
        President
       
      SIBLING INSIDERS II LLC
         
      By:

    /s/ Brian M. Isern

        Brian M. Isern
        President
       
      SIBLING INSIDERS FUND II L.P.
       
      By: Sibling Insiders II LLC, its general partner
         
      By:

    /s/ Brian M. Isern

        Brian M. Isern
        President

     

     

     

    Get the next $TCDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCDA

    DatePrice TargetRatingAnalyst
    4/13/2022$25.00Buy
    Goldman
    11/16/2021$7.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $TCDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tricida Announces Third Quarter 2022 Financial Results

      Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in October the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration

      11/14/22 4:05:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida Provides Strategic Update

      Tricida, Inc. (NASDAQ:TCDA), announced today that the Board of Directors has authorized Tricida to initiate a review of strategic alternatives to maximize stakeholder value. To facilitate this review, Tricida has engaged Stifel and its wholly owned affiliate, Miller Buckfire, to serve as investment banking advisors and SierraConstellation Partners LLC to serve as a financial advisor. This strategic review may include consideration of the sale of the Company and/or its assets. Tricida is also currently evaluating plans to reduce operating expenses and anticipates initiating and announcing these plans in November 2022. The Board of Directors and Tricida intend to conduct a thorough review of

      11/2/22 4:05:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

      Webcast today at 8:00 am Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). Primary Endpoint Analysis The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR), also known as DD40. One hundred forty-nine veverimer-treated patients versus 148 pla

      10/24/22 7:00:00 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Tricida Inc. (Amendment)

      SC 13G/A - Tricida, Inc. (0001595585) (Subject)

      2/14/23 4:16:07 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Tricida Inc. (Amendment)

      SC 13G/A - Tricida, Inc. (0001595585) (Subject)

      2/14/23 12:19:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Tricida Inc. (Amendment)

      SC 13G/A - Tricida, Inc. (0001595585) (Subject)

      2/14/23 8:58:08 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Tricida with a new price target

      Goldman initiated coverage of Tricida with a rating of Buy and set a new price target of $25.00

      4/13/22 7:21:51 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida upgraded by JP Morgan with a new price target

      JP Morgan upgraded Tricida from Underweight to Neutral and set a new price target of $7.00

      11/16/21 5:20:40 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Toragen, Inc. Announces Appointment of Dr. Sandra Coufal, M.D. as CEO

      Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today that Dr. Sandra Coufal, M.D. will join Toragen as its new CEO. Dr. Coufal brings over 30 years of experience to Toragen as a physician and serial entrepreneur working with multiple successful companies in medicine, chemistry, biotechnology, material sciences, and digital technology. This press release features multimedia. View the full release here: https://www.businesswire.c

      2/9/22 4:38:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Tricida Inc.

      EFFECT - Tricida, Inc. (0001595585) (Filer)

      6/20/23 12:15:13 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Tricida Inc.

      15-12G - Tricida, Inc. (0001595585) (Filer)

      6/13/23 6:55:49 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Tricida Inc.

      S-8 POS - Tricida, Inc. (0001595585) (Filer)

      6/13/23 6:53:19 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Financials

    Live finance-specific insights

    See more
    • Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

      Webcast today at 8:00 am Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). Primary Endpoint Analysis The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR), also known as DD40. One hundred forty-nine veverimer-treated patients versus 148 pla

      10/24/22 7:00:00 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida Announces Second Quarter 2022 Financial Results

      Webcast Today at 4:30 pm Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three and six months ended June 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in May 2022 that it stopped its VALOR-CKD renal outcomes trial early for administrative reasons as permitted by the existing study protocol to allow for six months of financial runway following the reporting of top-line results, which is anticipated to occur in October 2022. The VALOR-CKD trial has continued to accrue primary endpoint events as clinical trial subjects complete their participation in the study which, for the last subject, is currently projected to

      8/8/22 4:05:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 8, 2022

      SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022. Tricida will host a webcast and conference call at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows: Tricida Second Quarter Financial Results Conference CallMonday, August 8, 20224:30 pm Eastern Time  Webcast:IR.Tricida.com Dial-in:(800) 715-9871 International:(646) 307-1963 Conference ID:3576787 A replay of the webcast will be available on Tricida's website approximately two hours

      8/1/22 10:00:00 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Orbimed Advisors Llc sold $2,205,635 worth of shares (10,280,947 units at $0.21)

      4 - Tricida, Inc. (0001595585) (Issuer)

      11/25/22 8:13:12 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Bonita David P sold $2,205,635 worth of shares (10,280,947 units at $0.21)

      4 - Tricida, Inc. (0001595585) (Issuer)

      11/25/22 8:08:35 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Alpern Robert J sold $27,695 worth of shares (131,879 units at $0.21), closing all direct ownership in the company

      4 - Tricida, Inc. (0001595585) (Issuer)

      11/25/22 4:13:54 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care